ERBB4, erb-b2 receptor tyrosine kinase 4, 2066

N. diseases: 317; N. variants: 75
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma
0.700 AlteredExpression disease BEFREE The positive expression of HER4 was correlated with the prognosis of SNMMM patients (P<0.05). 29309357 2018
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE Here we want to share our experience regarding major problems associated with FFPE DNA used for PCR-based sequencing as illustrated by the mutational analysis of ERBB4 in melanoma. 28314930 2017
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE At the same time, high throughput sequencing studies of melanoma unraveled a series of new treatment candidates for future treatment approaches such as ERBB4, GRIN2A, GRM3, and RAC1. 25654738 2015
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE Our results further emphasize the role of HER4 as an important oncogene in malignant melanoma and point to HER4 as a possible drug target in this disease. 24366194 2014
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE This sequencing technique has successfully been applied within a clinical trial selecting patients with ERBB4-mutant melanoma for lapatinib treatment. 24258993 2014
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE Malignant transformation of melanomas is accompanied by loss of KIT and acquisition of EPO-R and ErbB4, both of which are co-expressed with NGF-R and PD-1 in distinct subfractions of melanoma cells. 24489649 2014
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a novel activating mutation of BRAF. 24628946 2014
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE Our results indicate that ERBB4 mutations may play a limited role in melanomas in China; therefore, targeting the ERBB4 mutation in melanoma patients from southern China may not be a promising strategy. 23237222 2013
CUI: C3715155
Disease: AMYOTROPHIC LATERAL SCLEROSIS 19
AMYOTROPHIC LATERAL SCLEROSIS 19
0.700 GeneticVariation disease UNIPROT ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. 24119685 2013
CUI: C3715155
Disease: AMYOTROPHIC LATERAL SCLEROSIS 19
AMYOTROPHIC LATERAL SCLEROSIS 19
0.700 Biomarker disease GENOMICS_ENGLAND ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. 24119685 2013
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE Ligand-mediated activation of ErbB3 and ErbB4 is implicated in the pathogenesis of several human malignancies including cancer of the ovary and melanoma. 22856597 2012
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE Gaining further understanding into the oncogenic mechanism of Erbb4 may not only help in the development of targeted therapy in melanoma patients but might accelerate the acceptance of a novel taxonomy of cancer which is based on the genomic perturbations in cancer genes and cancer gene families and their response to targeted agents. 20404484 2010
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease CTD_human Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib. 19718025 2009
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease BEFREE We found ERBB4 mutations in 19% of individuals with melanoma and found mutations in two other kinases (FLT1 and PTK2B) in 10% of individuals with melanomas. 19718025 2009
CUI: C0025202
Disease: melanoma
melanoma
0.700 Biomarker disease BEFREE A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. 19800573 2009
CUI: C0025202
Disease: melanoma
melanoma
0.700 GeneticVariation disease CLINVAR Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib. 19718025 2009
CUI: C0025202
Disease: melanoma
melanoma
0.700 CausalMutation disease CGI
CUI: C3715155
Disease: AMYOTROPHIC LATERAL SCLEROSIS 19
AMYOTROPHIC LATERAL SCLEROSIS 19
0.700 CausalMutation disease CLINVAR
CUI: C3715155
Disease: AMYOTROPHIC LATERAL SCLEROSIS 19
AMYOTROPHIC LATERAL SCLEROSIS 19
0.700 Biomarker disease GENOMICS_ENGLAND
CUI: C3715155
Disease: AMYOTROPHIC LATERAL SCLEROSIS 19
AMYOTROPHIC LATERAL SCLEROSIS 19
0.700 Biomarker disease CTD_human
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.500 Biomarker disease BEFREE This study has implications that miR-141 as well as its target, ERBB4, as a potential target for treating trastuzumab-resistant breast cancers. 30746756 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.500 Biomarker disease BEFREE Recent data suggest that HER4 unfavorably affects the endocrine treatment of postmenopausal breast cancer patients with tamoxifen and therefore might represent an additional therapeutic target in luminal breast cancer. 31139328 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.500 Biomarker disease BEFREE Recent data suggest that HER4 unfavorably affects the endocrine treatment of postmenopausal breast cancer patients with tamoxifen and therefore might represent an additional therapeutic target in luminal breast cancer. 31139328 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.500 AlteredExpression disease BEFREE Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4. 30746756 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.500 AlteredExpression disease BEFREE MED1 mediates induction of cell proliferation and migration and the genes associated with it (JUN, FOS, EGFR, VEGF, MMP1, and ERBB4) in breast cancer, which is abrogated when used together with miR-191-inhibition. 30087366 2018